Ira M. Jacobson

41.0k total citations · 11 hit papers
338 papers, 19.9k citations indexed

About

Ira M. Jacobson is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Ira M. Jacobson has authored 338 papers receiving a total of 19.9k indexed citations (citations by other indexed papers that have themselves been cited), including 285 papers in Hepatology, 239 papers in Epidemiology and 56 papers in Infectious Diseases. Recurrent topics in Ira M. Jacobson's work include Hepatitis C virus research (261 papers), Liver Disease Diagnosis and Treatment (168 papers) and Hepatitis B Virus Studies (153 papers). Ira M. Jacobson is often cited by papers focused on Hepatitis C virus research (261 papers), Liver Disease Diagnosis and Treatment (168 papers) and Hepatitis B Virus Studies (153 papers). Ira M. Jacobson collaborates with scholars based in United States, France and Germany. Ira M. Jacobson's co-authors include John G. McHutchison, Mark Sulkowski, Janice K. Albrecht, Fred Poordad, Eugene R. Schiff, Nezam H. Afdhal, Michael P. Manns, Clifford A. Brass, Stuart C. Gordon and Andrew H. Talal and has published in prestigious journals such as New England Journal of Medicine, Cell and The Lancet.

In The Last Decade

Ira M. Jacobson

326 papers receiving 19.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

2011 1.9k citations Mark Sulkowski, Ira M. Jacobson et al. profile →
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

1989 1.4k citations Gary L. Davis, Karen L. Lindsay et al. profile →
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

2012 1.3k citations Patrick Marcellin, Edward Gane et al. The Lancet profile →
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 803 citations John G. McHutchison, Gregory T. Everson et al. profile →
A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

1990 664 citations E. Schiff, Karen L. Lindsay et al. profile →
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

2018 603 citations Zobair M. Younossi, Maria Stepanova et al. Clinical Gastroenterology and Hepatology profile →
Telaprevir for Previously Treated Chronic HCV Infection

2010 529 citations John G. McHutchison, Norah A. Terrault et al. profile →
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

2010 515 citations Paul Y. Kwo, Eric Lawitz et al. The Lancet profile →
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 395 citations Ira M. Jacobson, Mark Sulkowski et al. profile →
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Ira M. Jacobson, Graham R. Foster et al. The Lancet profile →
Hepatitis C Virus RNA Functionally Sequesters miR-122

2015 268 citations Ype P. de Jong, Ira M. Jacobson et al. profile →

Peers

Countries citing papers authored by Ira M. Jacobson

Since Specialization

Citations

This map shows the geographic impact of Ira M. Jacobson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ira M. Jacobson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ira M. Jacobson more than expected).

Fields of papers citing papers by Ira M. Jacobson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ira M. Jacobson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ira M. Jacobson. The network helps show where Ira M. Jacobson may publish in the future.

Co-authorship network of co-authors of Ira M. Jacobson

This figure shows the co-authorship network connecting the top 25 collaborators of Ira M. Jacobson. A scholar is included among the top collaborators of Ira M. Jacobson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ira M. Jacobson. Ira M. Jacobson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HBV‐Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment 2024 ·Liver International ·Thomas Tu, Thomas McQuaid, Ira M. Jacobson	5
2	Chronic Hepatitis B 2023 ·Clinics in Liver Disease ·Feng Su, Ira M. Jacobson	4
3	Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices 2020 ·Alimentary Pharmacology & Therapeutics ·Zobair M. Younossi, Kathleen E. Corey, Naim Alkhouri, Mazen Noureddin, Ira M. Jacobson, Brian Lam, Stephen Clement, Rita Basu, Stuart C. Gordon, (unknown), Puneet Puri, Mary E. Rinella, (unknown), Ashwani K. Singal, Linda Henry	62
4	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy 2019 ·Gastroenterology ·Anna S. Lok, Mark Sulkowski, Jens Kort, Ira Willner, K. Rajender Reddy, Mitchell L. Shiffman, Mohamed A. Hassan, Brian L. Pearlman, Federico Hinestrosa, Ira M. Jacobson, Giuseppe Morelli, Joy Peter, Monika Vainorius, (unknown), Michael Fried, Gary P. Wang, Wenjing Lü, Lois Larsen, David R. Nelson	34
5	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016 2018 ·Journal of Viral Hepatitis ·Andrew A. Li, Donghee Kim, Won Kim, (unknown), (unknown), George Cholankeril, Ira M. Jacobson, Zobair M. Younossi, Aijaz Ahmed	13
6	The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis 2018 ·Journal of Viral Hepatitis ·Lawrence Serfaty, Ira M. Jacobson, Jürgen K. Rockstroh, Frederick L. Altice, Peggy Hwang, Eliav Barr, Michael Robertson, Barbara Haber	9
7	Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3 2017 ·Alimentary Pharmacology & Therapeutics ·Zobair M. Younossi, Maria Stepanova, Ira M. Jacobson, Tarik Asselah, Edward Gane, Eric Lawitz, Graham R. Foster, Stuart K. Roberts, A. Thompson, B. Willems, (unknown), Brian L. Pearlman, Issah Younossi, Andrei Racila, Linda Henry	34
8	Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log₁₀ copies/ml) 2014 ·Liver International ·Scott Fung, Stuart C. Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Šperl, Edward Gane, Ira M. Jacobson, Leland J. Yee, Phillip Dinh, Eduardo B. Martins, John F. Flaherty, Kathryn M. Kitrinos, Geoffrey Dusheiko, Huy N. Trinh, Robert Flisiak, Vinod K. Rustgi, Marı́a Buti, Patrick Marcellin	4
9	Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials 2014 ·Hepatology ·Steven L. Flamm, Edward Gane, Jean‐François Dufour, Vinod K. Rustgi, Vincent G. Bain, Dorothy H. Crawford, Pietro Andreoné, Tarek Hassanein, Włodzimierz Mazur, Sandra Lovell, (unknown), Nancy S. Shulman, Massimo Puoti, Terry Box, Ira M. Jacobson	4
10	Emerging Therapeutic Targets for Hepatitis C Virus Infection 2013 ·Clinical Gastroenterology and Hepatology ·Arun Jesudian, Ype P. de Jong, Ira M. Jacobson	11
11	P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study: Abstract P70 Table 1 2011 ·Gut ·Geoffrey Dusheiko, Leif Bengtsson, Nathalie Adda, Robert S. Kauffman, Ira M. Jacobson	48
12	2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS 2010 ·Journal of Hepatology ·Ira M. Jacobson, Paul J. Pockros, Jacob Lalezari, E. Läwitz, M. Rodríguez‐Torres, E DeJesus, Felix Haas, Claudia Martorell, (unknown), Vivek S. Purohit, Subasree Srinivasan, (unknown), Khurram Rana, Jennifer Hammond	18
13	1006 HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT 2010 ·Journal of Hepatology ·E. Gane, E.J. Heathcote, Patrick Marcellin, Geoffrey Dusheiko, Ira M. Jacobson, (unknown), Stefan Zeuzem, (unknown), J. Sorbel, Elsa Mondou, Jane Anderson, Franck Rousseau	12
14	Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy 2008 ·Clinical Gastroenterology and Hepatology ·David R. Nelson, Gary L. Davis, Ira M. Jacobson, Gregory T. Everson, Michael Fried, Stephen A. Harrison, Tarek Hassanein, Donald M. Jensen, Karen L. Lindsay, Norah A. Terrault, Nizar N. Zein	11
15	[649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA 2007 ·Journal of Hepatology ·(unknown), R. Ghalib, E. Läwitz, B. Freilich, Stuart C. Gordon, Paul Y. Kwo, Thomas Riley, E. Schiff, Steven L. Flamm, Ira M. Jacobson, Nizar N. Zein, Adrian Reuben, (unknown), David R. Bright, Mohammed Al-Adhami, Julie Lekstrom-Himes, Francesco Massari, John G. McHutchison	7
16	[786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C 2007 ·Journal of Hepatology ·John G. McHutchison, Gregory T. Everson, S. Gordon, Ira M. Jacobson, R. G. Kauffman, Lindsay McNair, (unknown)	19
17	Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT 2004 ·The American Journal of Gastroenterology ·Ira M. Jacobson, Furqaan Ahmed, Mark W. Russo, Edward Lebovics, Douglas T. Dieterich, Susanna Esposito, Nancy Bach, Franklin M. Klion, Hillel Tobias, (unknown), Robert S. Brown, (unknown), (unknown), Hulya Levendoglu	24
18	Chronic viral hepatitis diagnosis and therapeutics 2003 ·Gastroenterology ·(unknown), Ira M. Jacobson	7
19	Accumulation of B Lymphocytes with a Naive, Resting Phenotype in a Subset of Hepatitis C Patients 2003 ·The Journal of Immunology ·(unknown), (unknown), Adrian M. Di Bisceglie, Ira M. Jacobson, Andrew H. Talal, David Butera, Charles M. Rice, Thomas J. Chambers, Lynn B. Dustin	56
20	An unusual case of acute colitis 2000 ·The Lancet ·Brian R. Landzberg, Ira M. Jacobson	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact